›› 2010, Vol. 30 ›› Issue (12): 1525-.doi: 10.3969/j.issn.1674-8115.2010.12.019

• Original article (Clinical research) • Previous Articles     Next Articles

Effect of risperidone on sensory gating P50 deficit in patients with schizophrenia

LIU Deng-tang1,2, ZHUO Kai-ming1, SONG Zhen-hua1, WU Yan1, CHEN Xing-shi1, WANG Ji-jun1, YANG Zhi-liang2, XU Yi-feng1   

  1. 1.Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China；2.Department of Psychology, East China Normal University, Shanghai 200062, China
  • Online:2010-12-25 Published:2010-12-31
  • Supported by:

    Shanghai Clinical Center of Mental Disease Foundation, K-04-2；Shanghai Excellent Young Medical Tatents Cultivation Project；China Postdoctoral Science Foundation, 20080430634；Shanghai Science and Technology Committee Foundation, 07ZR14093；Shanghai Municipal Health Bureau Foundation,024036；Foundation from Janssen Research Council China, JRCC

PDF (PC)

1750

Abstract:

Objective To investigate the effect of atypical antipsychotic medicine risperidone on sensory gating P50 deficit in patients with schizophrenia. Methods Twenty-six patients with first-episode schizophrenia and 25 patients with chronic schizophrenia were enrolled in the study. All patients were treated with risperidone of different doses (2 to 6 mg/d). All patients fulfilled the evaluation of sensory gating P50 with the conditioning (S1)-testing (S2) paradigm before treatment and 4 to 6 weeks after treatment. The psychotic symptoms were assessed with Positive and Negative Syndrome Scale (PANSS), and the therapeutic effects were evaluated with PANSS reduction rate. Results There was no significant difference in P50 parameters between the two groups before treatment (P>0.05), and there was no significant correlation between P50 inhibition parameters and disease course, psychotic episodes and psychiatric symptoms (PANSS total score, positive symptoms score, negative symptoms score and general psychopathology symptoms score) of schizophrenia (P>0.05). Except the group main effect for S2 amplitude (P=0.02), there was no significant change for main effect and interaction of the other P50 parameters after treatment (P>0.05). The effect of risperidone on P50 parameters was not related to the therapeutic effect. Conclusion Deficit in sensory gating inhibition exists in both first-episode schizophrenia and chronic schizophrenia, and risperidone in not effective in treating the deficit in sensory gating inhibition of schizophrenia.

Key words: schizophrenia, auditory evoked potential P50, sensory gating, risperidone, medication